DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamazaki, H.
Right arrow Articles by Yokoi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamazaki, H.
Right arrow Articles by Yokoi, T.

Vol. 27, Issue 9, 999-1004, September 1999

Enhancement of Cytochrome P-450 3A4 Catalytic Activities by Cytochrome b5 in Bacterial Membranes

Hiroshi Yamazaki, Miki Nakajima, Mami Nakamura, Satoru Asahi, Noriaki Shimada, Elizabeth M. J. Gillam, F. Peter Guengerich, Tsutomu Shimada, and Tsuyoshi Yokoi

Faculty of Pharmaceutical Sciences, Kanazawa University, Kanazawa, Japan (H.Y., M. Nakajima, M. Nakamura, M. Nakajima, T.Y.); Takeda Chemical Industries, Ltd., Osaka, Japan (S.A.); Daiichi Pure Chemicals Co., Ibaraki, Japan (N.S.); Department of Physiology and Pharmacology, University of Queensland, St. Lucia, Queensland, Australia (E.M.J.G.); Department of Biochemistry and Center in Molecular Toxicology, Vanderbilt University School of Medicine, Nashville, Tennessee (F.P.G.); and Osaka Prefectural Institute of Public Health, Osaka, Japan (T.S.)

Activities of testosterone, nifedipine, and midazolam oxidation by recombinant cytochrome P-450 (P-450) 3A4 coexpressed with human NADPH-P-450 reductase (NPR) in bacterial membranes (CYP3A4/NPR membranes) were determined in comparison with those of other recombinant systems and of human liver microsomes with high contents of CYP3A4. Growth conditions for Escherichia coli transformed with the bicistronic construct affected expression levels of CYP3A4 and NPR; an excess of NPR over P-450 in membrane preparations enhanced CYP3A4-dependent testosterone 6beta -hydroxylation activities of the CYP3A4/NPR membranes. Cytochrome b5 (b5) and apolipoprotein b5 further enhanced the testosterone 6beta -hydroxylation activities of CYP3A4/NPR membranes after addition to either bacterial membranes or purified enzymes. NPR was observed to enhance catalytic activity when added to the CYP3A4/NPR membranes, either in the form of bacterial membranes or as purified NPR (in combination with cholate and b5). Apparent maximal activities of testosterone 6beta -hydroxylation in CYP3A4/NPR membranes were obtained when the molar ratio of CYP3A4/NPR/b5 was adjusted to 1:2:1 by mixing membranes containing each protein. Testosterone 6beta -hydroxylation, nifedipine oxidation, and midazolam 4- and 1'-hydroxylation activities in CYP3A4/NPR membranes plus b5 systems were similar to those measured with microsomes of insect cells coexpressing CYP3A4 with NPR and/or of human liver microsomes, based on equivalent CYP3A4 contents. These results suggest that CYP3A4/NPR membrane systems containing b5 are very useful models for prediction of the rates for liver microsomal CYP3A4-dependent drug oxidations.


Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
K. Maekawa, N. Harakawa, E. Sugiyama, M. Tohkin, S.-R. Kim, N. Kaniwa, N. Katori, R. Hasegawa, K. Yasuda, K. Kamide, et al.
Substrate-Dependent Functional Alterations of Seven CYP2C9 Variants Found in Japanese Subjects
Drug Metab. Dispos., September 1, 2009; 37(9): 1895 - 1903.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
L. Gan, L. L. von Moltke, L. A. Trepanier, J. S. Harmatz, D. J. Greenblatt, and M. H. Court
Role of NADPH-Cytochrome P450 Reductase and Cytochrome-b5/NADH-b5 Reductase in Variability of CYP3A Activity in Human Liver Microsomes
Drug Metab. Dispos., January 1, 2009; 37(1): 90 - 96.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
B. Carr, R. Norcross, Y. Fang, P. Lu, A. D. Rodrigues, M. Shou, T. Rushmore, and C. Booth-Genthe
Characterization of the Rhesus Monkey CYP3A64 Enzyme: Species Comparisons of CYP3A Substrate Specificity and Kinetics Using Baculovirus-Expressed Recombinant Enzymes
Drug Metab. Dispos., October 1, 2006; 34(10): 1703 - 1712.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
J. S. McCune, L. J. Risler, B. R. Phillips, K. E. Thummel, D. Blough, and D. D. Shen
CONTRIBUTION OF CYP3A5 TO HEPATIC AND RENAL IFOSFAMIDE N-DECHLOROETHYLATION
Drug Metab. Dispos., July 1, 2005; 33(7): 1074 - 1081.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
Y.-H. Wang, D. R. Jones, and S. D. Hall
DIFFERENTIAL MECHANISM-BASED INHIBITION OF CYP3A4 AND CYP3A5 BY VERAPAMIL
Drug Metab. Dispos., May 1, 2005; 33(5): 664 - 671.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
T. M. Klees, P. Sheffels, O. Dale, and E. D. Kharasch
METABOLISM OF ALFENTANIL BY CYTOCHROME P4503A (CYP3A) ENZYMES
Drug Metab. Dispos., March 1, 2005; 33(3): 303 - 311.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
M. P. Duarte, B. B. Palma, A. A. Gilep, A. Laires, J. S. Oliveira, S. A. Usanov, J. Rueff, and M. Kranendonk
The stimulatory role of human cytochrome b5 in the bioactivation activities of human CYP1A2, 2A6 and 2E1: a new cell expression system to study cytochrome P450 mediated biotransformation
Mutagenesis, March 1, 2005; 20(2): 93 - 100.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
W. Huang, Y. S. Lin, D. J. McConn II, J. C. Calamia, R. A. Totah, N. Isoherranen, M. Glodowski, and K. E. Thummel
EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM
Drug Metab. Dispos., December 1, 2004; 32(12): 1434 - 1445.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
L. A. McConnachie, B. Phillips, M. Bajpai, D. D. Shen, and R. J. Y. Ho
ONLY TRUNCATED, NOT COMPLETE CYTOCHROME P450 2D6 RNA TRANSCRIPT AND NO DETECTABLE ENZYME ACTIVITY ARE EXPRESSED IN HUMAN LYMPHOCYTES
Drug Metab. Dispos., September 1, 2003; 31(9): 1103 - 1107.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. J. Lee, M. X. Cai, P. E. Thomas, A. H. Conney, and B. T. Zhu
Characterization of the Oxidative Metabolites of 17{beta}-Estradiol and Estrone Formed by 15 Selectively Expressed Human Cytochrome P450 Isoforms
Endocrinology, August 1, 2003; 144(8): 3382 - 3398.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. C. Patki, L. L. von Moltke, and D. J. Greenblatt
IN VITRO METABOLISM OF MIDAZOLAM, TRIAZOLAM, NIFEDIPINE, AND TESTOSTERONE BY HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROMES P450: ROLE OF CYP3A4 AND CYP3A5
Drug Metab. Dispos., July 1, 2003; 31(7): 938 - 944.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. A. Usmani, R. L. Rose, and E. Hodgson
Inhibition and Activation of the Human Liver Microsomal and Human Cytochrome P450 3A4 Metabolism of Testosterone by Deployment-Related Chemicals
Drug Metab. Dispos., April 1, 2003; 31(4): 384 - 391.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
C. Chen and D. R. Thakker
The Fallacy of Using Adrenochrome Reaction for Measurement of Reactive Oxygen Species Formed During Cytochrome P450-Mediated Metabolism of Xenobiotics
J. Pharmacol. Exp. Ther., February 1, 2002; 300(2): 417 - 420.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
N. Hatanaka, H. Yamazaki, R. Kizu, K. Hayakawa, Y. Aoki, M. Iwanari, M. Nakajima, and T. Yokoi
Induction of cytochrome P450 1B1 in lung, liver and kidney of rats exposed to diesel exhaust
Carcinogenesis, December 1, 2001; 22(12): 2033 - 2038.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
D. F. McGinnity, A. J. Parker, M. Soars, and R. J. Riley
Automated Definition of the Enzymology of Drug Oxidation by the Major Human Drug Metabolizing Cytochrome P450s
Drug Metab. Dispos., November 1, 2000; 28(11): 1327 - 1334.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
T. Komatsu, H. Yamazaki, S. Asahi, E. M. J. Gillam, F. P. Guengerich, M. Nakajima, and T. Yokoi
Formation of A Dihydroxy Metabolite of Phenytoin in Human Liver Microsomes/cytosol: Roles of Cytochromes P450 2c9, 2c19, and 3a4
Drug Metab. Dispos., November 1, 2000; 28(11): 1361 - 1368.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
H. Yamazaki, T. Shimada, M. V. Martin, and F. P. Guengerich
Stimulation of Cytochrome P450 Reactions by Apo-cytochrome b5. EVIDENCE AGAINST TRANSFER OF HEME FROM CYTOCHROME P450 3A4 TO APO-CYTOCHROME b5 OR HEME OXYGENASE
J. Biol. Chem., August 10, 2001; 276(33): 30885 - 30891.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.